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Lysine acetylation is a reversible post-translational modification (PTM) of cellular proteins and
represents an important regulatory switch in signal transduction. Lysine acetylation, in combination
with other PTMs, directs the outcomes as well as the activation levels of important signal transduction
pathways such as the nuclear factor (NF)-kB pathway. Small molecule modulators of the ‘writers’ (HATs)
and ‘erasers’ (HDACs) can regulate the NF-kB pathway in a specific manner. This review focuses on the
effects of frequently used HAT and HDAC inhibitors on the NF-kB signal transduction pathway and
inflammatory responses, and their potential as novel therapeutics.Introduction
Lysine acetylation is a reversible post-translational modification
(PTM) of cellular proteins and represents an important regulatory
switch in signal transduction cascades [1,2]. An increasing num-
ber of studies highlight the importance of lysine acetylation as a
key PTM, directing the outcomes as well as the activation levels of
important signal transduction pathways such as the nuclear
factor (NF)-kB pathway. For example, acetylation of NF-kB tran-
scription factors p65 and p50 plays an important part in their
nuclear localization and transcriptional activity [3]. Similar phe-
nomena have been observed for other pathways [4]. Next to this,
acetylation of histones connected to specific genes has an impor-
tant role in gene-specific transcription in the NF-kB pathway [3].
Furthermore, an increasing number of reports describe significant
levels of crosstalk between lysine acetylation and other PTMs,
such as ubiquitinylation, methylation and phosphorylation, in
the NF-kB pathway. For example, competition between acetyla-
tion and ubiquitinylation on the same lysine residues is observed
for transcription factor p65 [5]. This highlights the fact that
acetylation is not a sole determining factor but, rather, is aCorresponding author:. Dekker, F.J. (f.j.dekker@rug.nl)
654 www.drugdiscoverytoday.com 1359-6446/06  2013 The Authors. Published regulator working in concert with other PTMs at multiple levels
in signaling cascades.
Lysine acetylations are generally regulated by ‘writers’ and
‘erasers’, which are denoted as histone acetyltransferases (HATs)
and histone deacetylases (HDACs), respectively, owing to their
original discovery as histone-modifying enzymes. An important
future challenge is to identify and quantify distinct HAT and
HDAC activities in distinct signaling pathways such as the NF-
kB pathway, as well as their aberrations in disease (models). Con-
sidering the importance of lysine acetylation in the NF-kB pathway
(Fig. 1), small molecule modulators of HATs and HDACs have great
potential to regulate this signaling cascade specifically, which is an
important aim in drug discovery.
Focusing on the NF-kB pathway, here we summarize the effects of
lysine acetylation of the p65 transcription factor as well as histones.
In addition, we highlight the role of crosstalk between lysine
acetylation and other PTMs such as methylation and phosphoryla-
tion. Furthermore, we discuss the effects of frequently used small
molecule HAT and HDAC inhibitors on the NF-kB signal transduc-
tion pathway and inflammatory responses in vitro and in vivo.
Lysine acetylation as a regulator of the NF-kB pathway
In 2001, it was discovered that acetylation of p65 inhibits binding
to the inhibitory complex IkBa, and thus stimulates gene tran-
scription; whereas deacetylation promotes IkBa binding and
nuclear export [6]. This study triggered intense interest in lysineby Elsevier Ltd.  http://dx.doi.org/10.1016/j.drudis.2013.11.012Open access under CC BY-NC-SA license.
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FIGURE 1
Schematic representation of the diverse roles of lysine acetylation in the activation of the nuclear factor (NF)-kB pathway. Lysine acetylations of the transcription
factors as well as their co-activators play an important part in the duration of the response and the signaling output. Lysine acetylation status of the histones works
in concert with acetylation status of the transcription factors to enable or disable transcription of specific genes. Crosstalk of acetylation with other PTMs is an
important component in the NF-kB pathway. Abbreviations: HATs, histone acetyltransferases; HDACs, histone deacetylases.
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314, 315) of p65 that are subject to this PTM. These acetylations
have specific roles in activation of the NF-kB pathway and have
been previously reviewed [7,8]. Importantly: acetylation of lysines
122 and 123 decreases DNA binding [9]; acetylation at lysines 218
and 221 increases binding to kB enhancers; and acetylation at
lysine 310 is essential for full transcriptional activity [10]. In
addition, acetylations of specific lysine residues in histone H3
and H4 play an important part in NF-kB-mediated gene transcrip-
tion as reviewed [3].
Lysine acetylation does not act alone: crosstalk
between lysine acetylation and other PTMs
The acetylation of lysine residues in the NF-kB transcription factor
and in histones (and numerous other cellular targets) can be
dramatically affected by the PTM state of other constituent amino
acids. These so-called ‘crosstalk’ mechanisms act, presumably, via
increasing or decreasing the affinity of the substrate protein for the
respective HAT or HDAC complexes involved in their acetylation.
A recent review nicely illustrates the importance of crosstalk
between PTMs on the NF-kB transcription factor [8]. In addition,
previous reviews illustrate the importance of crosstalk between
lysine acetylation and other PTMs in the histones [11–14]. Here,
we highlight some specific examples that demonstrate the crucial
involvement of crosstalk in NF-kB activation as well as in histones
implicated in inflammation. The examples described below are
limited to known cases of crosstalk within the same protein (cis
crosstalk). In addition, a growing number of examples make it
clear that similar mechanisms also operate in modulating protein–
protein interactions including those between the peptides tails of
different histones (trans crosstalk).
A specific example of crosstalk in the NF-kB pathway involves
the phosphorylations of p65 at serines 276 and 536, which serves
to enhance the p300-mediated acetylation of lysine 310. This, inturn, leads to an overall transcriptional activation of the NF-kB
pathway (Fig. 2a) [15]. In addition, it has been found that phos-
phorylation of serine 276 is required for binding of p65 to the
coactivator CREB-binding protein (CBP), which promotes proin-
flammatory gene transcription.
Phosphorylation also has a major role in the crosstalk observed
within histone proteins. One of the earliest reported and best-
studied examples of crosstalk in histones involves the phosphor-
ylation of serine 10 in histone 3 (H3S10) and its effect on lysine
acetylation (Fig. 2b). Several kinases are known to phosphorylate
H3S10. These include AuroraB and other members of the Aurora/
Ipl 1 kinase family, as well as kinases implicated in transcriptional
regulation such as the yeast non-specific serine/threonine protein
kinase 1 (Snf1) and mammalian Proto-oncogene serine/threonine
protein kinase 1 (Pim1), Ribosomal s6 kinase (Rsk), Mitogen and
stress activated kinase 1 (Msk1), and Mitogen and stress activated
kinase 2 (Msk2) kinases [16–18]. Phosphorylation of H3S10 leads
to the stimulation of acetylation at lysine 14 (H3K14) with the
prototypical histone acetyltransferase general control nondere-
pressible (Gcn)5 displaying an up to tenfold preference for acet-
ylation of H3K14 when H3S10 is phosphorylated [19,20]. In
contrast to the enhancement of acetylation at H3K14, phosphor-
ylation of H3S10 completely blocks acetylation at the directly
adjacent lysine 9 (H3K9) residue [21], clearly illustrating the
varying crosstalk effects that the same PTM can impart.
In addition to serine phosphorylation, the methylation of lysine
and arginine side chains is another common PTM known to
impact lysine acetylation via crosstalk. The side chain of lysine
can be mono-, di- or tri-methylated, often with varying crosstalk
effects (Fig. 2c). For example, lysine methylation at lysine 4 in
histone H3 (H3K4) leads to increased acetylation of H3K14 and
other lysine residues in histone H3 by p300 and other acetyltrans-
ferases [22]. Further evidence suggests that the degree to which
H3K4 is methylated directly influences the associated extent ofwww.drugdiscoverytoday.com 655
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FIGURE 2
Examples of various post-translational modifications (PTMs) and their crosstalk interactions with lysine acetylation in the p65 transcription factor and histone
proteins. Abbreviation: NF-kB, nuclear factor kB.
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NH3 acetylation [23]. As a result, the trimethylation of H3K4 is
generally seen as a marker for transcriptional activation given its
direct role in promoting acetylation. Conversely, trimethylation
of lysine 9 in histone 3 (H3K9) is linked to transcriptional repres-
sion and is associated with reduced histone H3 acetylation. In vitro
studies have revealed that trimethylation of H3K9 leads to inhibi-
tion of H3 acetylation at lysines 14, 18 and 23 [23]. Given their
opposing effects, it is perhaps not surprising that methylations of
H3H4 and H3K9 appear to be mutually exclusive [22,24,25].
Likewise, the arginine side chain can be either mono-methylated
or, more commonly, di-methylated to yield either asymmetric or656 www.drugdiscoverytoday.comsymmetric dimethyl arginine. Interestingly, numerous examples of
crosstalk between arginine methylation and lysine acetylation are
known. A specific example involves the asymmetric dimethylation
of arginine 3 in histone 4 (H4R3) by protein arginine N-methyl-
transferase (PRMT)1, which leads to increased histone 4 acetylation
by p300, with the largest enhancement observed for acetylation at
lysine 8 and 12 (Fig. 2d) [26]. Given its role in promoting H4
acetylation, the asymmetric dimethylation of H4R3 by PRMT1 is
generally associated with the activation of gene transcription. In a
striking example of the subtleties at play in histone crosstalk, it
has also been found that symmetric dimethylation at H4R3, as
Drug Discovery Today  Volume 19, Number 5 May 2014 REVIEWS
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PRMT1 (Fig. 2d). Counter to asymmetric dimethylation at H4R3,
the PRMT5-mediated symmetric dimethylation of the same
arginine residue is associated with deacetylation of H4 and leads
to repressed transcription [27,28]. In addition, a recent report by
Zheng and colleagues has shown that the acetylation of lysine 5
in histone 4 differentially affects methylation at H4R3 [29].
Acetylation of H4K5 was found to deactivate the asymmetric
dimethylation of H4R3 by PRMT1 while enhancing symmetric
dimethylation at the same arginine by PRMT5. From this, it is
clear that crosstalk mechanisms play a significant part in acet-
ylation of the p65 transcription factor and histones. Exploiting
such mechanisms could provide avenues for the development of
novel therapeutics designed to affect acetylation.
HATs in the NF-kB pathway
On the basis of their primary structure homology, HATs have been
divided into five families. Three families that have been studied
extensively are the Gcn5-related N-acetyltransferase (GNAT) family,
represented by p300/CBP-associated factor (PCAF) and Gcn5; the
p300/CBP family, including CBP and p300; and the MYST (the
acronym MYST derives from the four founding members of this
HAT family: mammalian MOZ, yeast Y bf2/Sas3 and Sas2, and
mammalian Tip60) family including males absent on the first
(MOF) and TAT-interacting protein 60 (Tip60) [30]. The HATs
p300 and PCAF acetylate lysines 122 and 123 of p65 [9] and p300
has been described to acetylate lysines 310, 314 and 315 [31]. The
role of HATs in acetylation of the NF-kB transcription factor as well
as acetylation of the histones connected to kB promoters has been
reviewed [3]. Interestingly, a recent study demonstrates that Tip60 is
a co-activator of several NF-kB target genes and exerts its action via
protein–protein interactions with p65. It appears that Tip60 bindsPan-HDAC inhibitors
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FIGURE 3
Structures of small molecules that interact with writers (histone acetyltransferaseearlier to the kB promoters than p65 and simultaneously promotes
histone acetylation, which indicates that Tip60 could serve as a
platform to promote NF-kB-mediated gene transcription [32].
HAT inhibitors mainly lead to inhibition of the NF-kB
pathway
Several inhibitors of histone acetyltransferases are known and
have been previously reviewed [3,33]. The natural product ana-
cardic acid (Fig. 3, Table 1) is a small molecule inhibitor of HATs
such as p300 and PCAF [34] and inhibits NF-kB-mediated gene
transcription [35]. This inhibitor has been used as a starting point
for the development of novel inhibitors such as the alkylidene
malonates [36]. The novel anacardic acid derivative MG149 (Fig. 3,
Table 1) demonstrates selectivity toward the MYST type of HATs:
Tip60 and MOF [37], and this molecule effectively suppresses
suberanilohydroxamic acid (SAHA)-induced hyperacetylation
[38]. In addition, DNA microarrays demonstrated that MG149
inhibits the p53 and the NF-kB pathways, as well as a very limited
number of other pathways [38].
Next to this, HTS identified the isothiazolones as HAT inhibitors
[39]. However, attempts to optimize this class failed to give inhi-
bitors with higher potency and selectivity [40–42], which could
mainly be attributed to the exceptionally high reactivity of iso-
thiazolones for thiolates [43]. Fortuitously, virtual screening
enabled the identification of C646 (Fig. 3, Table 1) as the first
potent, selective and cell-permeable p300 HAT inhibitor (Ki
0.4 mM) [44]. In addition, another recent virtual screening study
describes the identification of a novel cell-permeable inhibitor
(compound 2, Fig. 3, Table 1) of p300, which is active at the same
concentrations as C646 [45]. This demonstrates the strength of
virtual screening as a strategy for identification of novel inhibitors
for challenging targets such as HATs.H
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s; HATs) or erasers (histone deacetylase; HDACs) of lysine acetylations.
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TABLE 1
Small molecules that interfere with writers (HATs) or erasers (HDACs) of lysine acetylations, and their selectivity and effects on disease
models for NF-kB-mediated inflammation
Compound Selectivity Effects in disease models Refs
HAT inhibitors
Anacardic acid p300 and PCAF inhibitor Inhibits the NF-kB pathway [35]
MG149 Tip60 and MOF selective inhibitor Inhibits SAHA-induced hyperacetylation [37,38]
Inhibits the NF-kB and p53 signaling pathways
C646 p300 selective inhibitor (Ki 0.4 mM) Increases apoptosis by inhibition of the androgen receptor and
NF-kB pathway
[44,46,47]
Repression of gene expression
Inhibition of COX-2 expression
Compound 2 (Fig. 3) p300 HAT inhibitor (IC50 3.4 mM) – [45]
HDAC inhibitors or activators
SAHA Pan-HDAC inhibitor Suppression of LPS-induced cytokine release in vitro and in vivo [50,62]
Trichostatin A (TSA) Pan-HDAC inhibitor Inhibition of TNFa in vitro [49,62]
LBH580 (panobinostat) Pan-HDAC inhibitor Enhances NF-kB activation [61,62]
ITF2357 (givinostat) Pan-HDAC inhibitor Therapeutic benefit in patients suffering from juvenile idiopathic arthritis [56,62]
Compound 1 (Fig. 3) Unknown Inhibition of IL6, PGE2, TNFa and NO in RAW 264.7 macrophages [55]
Anti-inflammatory in paw edema mouse model
MS275 (Entinostat) HDAC1-3 selective inhibitor Enhances NF-kB activation [58,62]
TFMO 1 Class IIa selective inhibitor – [63]
SRTCX1003 SIRT1 activator Inhibits NF-kB activation [67]
COX, cyclooxygenase; HDAC, histone deacetylase; IL, interleukin; LPS, lipopolysaccharide; MOF, males absent on the first; NF-kB, nuclear factor kB; NO, nitric oxide; PCAF, p300/CBP
associated factor; PGE, prostaglandin E; RAW, Abelson murine leukemia virus transformed; SAHA, suberanilohydroxamic acid; SIRT, Sirtuin; Tip60, TAT-interacting protein 60; TNF, tumor
necrosis factor.
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prostate cancer cell lines demonstrated that siRNA-mediated and
C646-mediated inhibition of p300 increase apoptosis, which is,
among other things, caused by inhibition of the androgen recep-
tor and the NF-kB pathway [46]. Another group demonstrated
that p300 binds to the cyclooxygenase (COX)-2 promoter, and
that inhibition of p300 activity by C646 diminished the p300
promoter binding and the expression of COX-2. Interestingly,
this study was done in animal models in which C646 was admi-
nistered via a lumbar intrathecal catheter, which demonstrates
that HAT inhibitors can be administered locally in animal models
[47]. Taken together these data demonstrate that C646 performs
very well in cell-based studies and upon local administration in
animal models. Inhibition of p300 by siRNA and the chemical
inhibitor C646 leads to subsequent inhibition of, among others,
the NF-kB pathway.
HDAC classes
The HDACs are a highly homologous group of enzymes that are
classified based on their primary and secondary structure. The
zinc-binding HDACs are denoted class I (HDAC 1, 2, 3 and 8), class
IIa (HDAC 4, 5, 7 and 9), class IIb (HDAC 6 and 10) and class IV
(HDAC 11). In addition, there is a group of NAD+-dependent
HDACs, which are denoted class III (sirtuin 1–7) [48].
Inhibitors of zinc-dependent HDACs have ambiguous
effects on the NF-kB pathway
Although HDAC inhibitors were initially discovered as anticancer
agents, many studies indicate their ability to suppress inflamma-
tory responses. In this respect, early evidence stems from a study
demonstrating that phenylbutyrate and trichostatin A (Fig. 3,
Table 1) inhibit tumor necrosis factor (TNF)a expression in
inflamed tissues in a rheumatoid arthritis animal model [49].
Another early study demonstrates that HDAC inhibitor SAHA658 www.drugdiscoverytoday.com(Fig. 3, Table 1) inhibits lipopolysaccharide (LPS)-induced cyto-
kine release in vitro and in vivo [50]. Interestingly, this anti-inflam-
matory effect was observed at much lower concentrations than
tumor suppressive effects in vitro. The anti-inflammatory potency
of HDAC inhibitors has been described in several reviews [51–53].
It was observed that HDAC inhibitors such as SAHA and Trichos-
tatin A (TSA) delay and reduce NF-kB nuclear translocation and
gene expression upon TNFa stimulation [54]. The potential of
HDAC inhibitors to suppress inflammation is also nicely illu-
strated by compound 1, recently described by Lee et al. (Fig. 3,
Table 1) [55]. This novel HDAC inhibitor exhibits nanomolar
HDAC inhibitory potency and demonstrated a strong suppressive
effect on inflammatory mediator expression in animal models.
Most interestingly, a recent study applied the HDAC inhibitor
givinostat (Fig. 3, Table 1) in a relatively small patient group
suffering from systemic-onset juvenile idiopathic arthritis, and
demonstrated a clear therapeutic benefit and excellent safety
profile [56].
In contrast to inhibiting inflammation, other studies have also
demonstrated that certain HDAC inhibitors can also lead to the
stimulation of proinflammatory gene transcription. Initial studies
on NF-kB acetylation reported that HDACs 1–3 (class I) can dea-
cetylate p65 and negatively regulate gene transcription [6,57]. In
addition, HDAC activity leads to histone deacetylation, which is
generally associated with inhibition of gene transcription. Both
factors imply that HDAC inhibitors stimulate proinflammatory
gene transcription, which is supported by several studies. Indeed,
it was demonstrated that SAHA [58], TSA [59,60], MS275 [58,61,62]
and LBH589 [61] enhance NF-kB activation (Fig. 3, Table 1).
Toward elucidation and selective modulation of specific
HDACs in the NF-kB pathway
Such contradictory findings can be explained by applications of
different cell types and the lack of selectivity of the employed
Drug Discovery Today  Volume 19, Number 5 May 2014 REVIEWS
R
ev
ie
w
s
 P
O
S
T
S
C
R
E
E
NHDAC inhibitors. Most frequently, applied HDAC inhibitors target
all zinc-dependent HDACs, because most rely on the strongly zinc-
coordinating hydroxamic acid functionality (carried by pan-
HDAC inhibitors; Fig. 3, Table 1) [62]. This hampers elucidation
of the relevance of HDAC activity in specific disease models.
However, over the past few years, more selective inhibitors have
become available. An example includes entinostat/MS275 (Fig. 3,
Table 1), which is HDAC1–3 (class I) selective [62]. Also, the first
HDAC class IIa (HDAC 4, 5, 7 and 9) selective inhibitors with a
trifluoromethyloxadiazole scaffold (TFMO; Fig. 3, Table 1) were
recently identified [63]. Interestingly, this novel class of inhibitors
lacks the usual hallmark of class I and class IIb inhibition: cell
death or apoptosis. This is beneficial for applications in non-
oncology areas such as inflammation.
Several studies have already shed more light on the role of
specific HDACs in the NF-kB pathway. A noteworthy recent study
reports that HDAC3 deacetylates p65 on lysines 122, 123, 314 and
315, and that it is a positive regulator of inflammatory gene
expression [64], which might seem contradictory to the previously
mentioned initial studies [6,57] and studies using MS275
[58,61,62]. However, note that these concern not only HDAC3
but also HDAC1 and 2. This indicates that future studies should be
aimed at developing more selective HDAC inhibitors that target,
for example, HDAC3. Additionally, there have also been interest-
ing reports on the role of SIRT type HDACs in the NF-kB pathway
[65]. For example, HDAC SIRT1 deacetylates p65 at lysine 310 and
thus inhibits the NF-kB transcriptional activity [66]. Interestingly,
the small molecule SIRT1 activator SRTCX1003 (Fig. 3, Table 1)
inhibits NF-kB activation in vitro and LPS-induced production of
proinflammatory cytokines in BALB/c mice [67]. Also, SIRT2 inter-
acts with p65, and deacetylates lysine 310, thereby inhibiting NF-
kB transcriptional activity. Sirt2 knockdown results in increased
expression of a subset of NF-kB target genes, indicating involve-
ment of Sirt2 in the expression of a subset of NF-kB target genes
[68]. This suggests that SIRT activators have a good potential for
further development into molecules that suppress NF-kB activa-
tion in inflammation.
Concluding remarks
Lysine acetylation is a key regulator of the NF-kB pathway, which
works in concert with other PTMs via complex crosstalk mechan-
isms to determine the signaling output. Importantly, small mole-
cule modulators of its writers (HATs) or erasers (HDACs) have
been demonstrated to regulate NF-kB signaling, suggesting that
these are potential drugs for inflammatory diseases. An ongoing
challenge toward regulation of the NF-kB pathway is the devel-
opment of highly potent molecules that selectively target specific
HATs or HDACs. Fortuitously, this field has seen remarkableprogress over the past few years. Several inhibitors now demon-
strate specific effects in distinct disease models in cellular systems
and animal studies, which is very promising for drug discovery. A
noteworthy example is HAT inhibitor C646. Owing to its high
selectivity and potency for p300, this inhibitor mainly leads to
inhibition of pathways that are connected to NF-kB, the andro-
gen receptor and the glucocorticoid receptor in cellular and
animal models. Another promising example is HAT inhibitor
MG149, which mainly inhibits expression related to the NF-kB
and p53 pathways.
Additionally, some currently described HDAC inhibitors show
encouraging effects in animal models and even patients; pan-
HDAC inhibitor givinostat displayed promising therapeutic ben-
efits in patients suffering from juvenile idiopathic arthritis. An
important consideration in the development of such agents is the
capacity for HDAC inhibitors to show either activation or inhibi-
tion of inflammatory responses. We presume that a main cause of
these ambiguities is that different reports employed different cell
types. In addition, we speculate that they could also be explained
by HDAC (non) selectivity of the inhibitors used. In the light of
this, it is interesting that a recent study demonstrated that HDAC3
is a positive regulator of inflammatory gene expression, which
deacetylates p65 on four specific lysines. This suggests that
HDAC3-specific inhibitors, and perhaps more specific inhibitors
for other HDACs, could unambiguously suppress inflammatory
responses. Also, the role of studied SIRT type HDACs seems to be
mainly inhibition of NF-kB gene transcription and, in line with
this, SIRT1 activator SRTCX1003 encouragingly reduced inflam-
matory responses in mice. This indicates that activators of SIRT
type HDACs could be also be effective in suppressing inflammatory
responses. However, it often remains unclear which specific
HDACs need to be targeted by inhibitors or activators. Thus, a
challenge lies ahead in determining whether specific HDACs target
specific lysine acetylations in specific signaling cascades, or if their
effects are (much) broader (a challenge which also still applies to
HATs). Finally, in addition to the current approaches of pursuing
modulators of HDACs and HATs, agents capable of inhibiting (or
enhancing) the various enzymes that install PTMs that crosstalk
with acetylation could also find use as drugs for modulating
histone (de)acetylation.
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